Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 345

Sort by

Sort Order Select

Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood (2024) 144 (23): 2389–2401.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Blood (2024) 144 (Supplement 1): 4654.

https://doi.org/10.1182/blood-2024-208308

Published: 2024

Journal Articles

Characterization of the Tumor Microenvironment of Diagnostic Bone Marrow Core Biopsies from African American Multiple Myeloma Patients Using Imaging Mass Cytometry

Anthony Colombo, Esther Lam, Ben Falk, Anton Luis Villamejor, Amie Hwang, Jose Aparicio, Jia Yin Wan, Chun R. Chao, Mallory Bernstein, Ravi Vij, Mark Fiala, Pei Lin, Robert Z. Orlowski, Imran Siddiqi, David Conti, Akil Merchant, Wendy Cozen

Blood (2024) 144 (Supplement 1): 3327.

https://doi.org/10.1182/blood-2024-208818

Published: 2024

Journal Articles

Feasibility and Implementation of the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Blood (2024) 144 (Supplement 1): 2393.

https://doi.org/10.1182/blood-2024-203892

Published: 2024

Journal Articles

Initial Results from the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Blood (2024) 144 (Supplement 1): 1972.

https://doi.org/10.1182/blood-2024-210377

Published: 2024

Journal Articles

Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network

Blood (2024) 144 (Supplement 1): 3792.5.

https://doi.org/10.1182/blood-2024-210957

Published: 2024

Journal Articles

Evaluating Diagnostic Performance of Light Chain Dimerization By Mass Spectrometry to Distinguish between AL Amyloidosis and Monoclonal Gammopathy of Undetermined Significance

Alexa Loncharich, Mark Fiala, Julie Fortier, Keith Stockerl-Goldstein, Ravi Vij, Mark A. Schroeder, Mark Zaydman, Michael Slade, Mariya Liyasova

Blood (2024) 144 (Supplement 1): 1921.

https://doi.org/10.1182/blood-2024-211395

Published: 2024

Journal Articles

Impact of Absolute Lymphocyte Counts (ALC) on Outcomes Following Bispecific Antibody Therapy in Patients with Relapsed/Refractory Multiple Myeloma Patients: A Single Center Real-World Experience

Yash Shah, Mark Fiala, Keith Stockerl-Goldstein, Mark A. Schroeder, Ravi Vij, Zachary D. Crees, Michael Slade

Blood (2024) 144 (Supplement 1): 3792.1.

https://doi.org/10.1182/blood-2024-209293

Published: 2024

Journal Articles

Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Blood (2024) 144 (Supplement 1): 3388.

https://doi.org/10.1182/blood-2024-200829

Published: 2024

Journal Articles

Clinical Outcomes in Black Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 Monumental-1 Study

Blood (2024) 144 (Supplement 1): 3357.

https://doi.org/10.1182/blood-2024-199797

Published: 2024

Journal Articles

Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Blood (2024) 144 (Supplement 1): 224.

https://doi.org/10.1182/blood-2024-201694

Published: 2024

Journal Articles

Convenience Versus Continuity: A Natural History Study of a Newly Opened Plasma Cell Disorders Clinic in an Underserved Community and Desire for Transfer of Care Among Previously Diagnosed Patients

Michael Slade, Ravi Vij, Keith Stockerl-Goldstein, Mark A. Schroeder, Angela Vickroy, Margaret Kavanaugh, Carmen Wilson, Mark Fiala

Blood (2024) 144 (Supplement 1): 3653.

https://doi.org/10.1182/blood-2024-203469

Published: 2024

Journal Articles

Real-World Experience with Elotuzumab, Pomalidomide, and Dexamethasone As Second or Third-Line Therapy in Relapsed and Refractory Multiple Myeloma

Akhil Kesaraju, Alexa Loncharich, Keith Stockerl-Goldstein, Mark A. Schroeder, Angela Vickroy, Ravi Vij, Michael Slade

Blood (2024) 144 (Supplement 1): 6936.

https://doi.org/10.1182/blood-2024-208241

Published: 2024

Journal Articles

Outcomes of Patients with Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from the LocoMMotion + MoMMent Studies

Blood (2023) 142 (Supplement 1): 4698.

https://doi.org/10.1182/blood-2023-181235

Published: 2023

Journal Articles

Novel Assay for Quantification of Free Light Chain (FLC) Dimers in Serum of Patients with Plasma Cell Dyscrasias

Mariya Liyasova, Michael Slade, Julie Fortier, Ravi Vij, Mark Fiala, Liqiang Yang, Bin Ma

Blood (2023) 142 (Supplement 1): 2292.

https://doi.org/10.1182/blood-2023-186583

Published: 2023

Journal Articles

Treatment Patterns and Outcomes for Patients with Newly Diagnosed Multiple Myeloma Post-Stem Cell Transplantation Who Received Lenalidomide As First Line Maintenance Therapy (PREAMBLE)

Ravi Vij, Suvina Amin, Jin Gu, Thomas S. Marshall, Susan Fish, Sujith Dhanasiri, Gabriela Hernandez, David Cella, Hartmut Goldschmidt, Karthik Ramasamy

Blood (2023) 142 (Supplement 1): 3786.

https://doi.org/10.1182/blood-2023-178500

Published: 2023

Journal Articles

Selinexor, Ixazomib, Pomalidomide and Dexamethasone in Functionally High-Risk Multiple Myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) Sub-Protocol Y3

Joshua Richter, Jeffrey A. Zonder, Nitya Nathwani, Giada Bianchi, Craig C. Hofmeister, Ravi Vij, Matthew Pianko, Gurbakhash Kaur, Malin Hultcrantz, Katie Wozniak, Mercedes Martillo, Hearn Jay Cho, Shaji Kunnathu Kumar

Blood (2023) 142 (Supplement 1): 3387.

https://doi.org/10.1182/blood-2023-184949

Published: 2023

Journal Articles

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Blood (2023) 142 (Supplement 1): 1028.

https://doi.org/10.1182/blood-2023-178933

Published: 2023

Journal Articles

Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3378.

https://doi.org/10.1182/blood-2023-182388

Published: 2023

Journal Articles

Use of Combination Premedication Prior to Motixafortide Administration Reduced Severity and Frequency of AEs in the Phase 3 Genesis Trial - a Single Center Analysis

Zachary David Crees, Keith Stockerl-Goldstein, Mark A. Schroeder, Ravi Vij, Ella Sorani, Irit Gliko Kabir, Inbal Goldstein, Tzipi Lustig, Shaul Kadosh, John F. DiPersio

Blood (2023) 142 (Supplement 1): 3522.

https://doi.org/10.1182/blood-2023-181452

Published: 2023

NARROW

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Characterization of the Tumor Microenvironment of Diagnostic Bone Marrow Core Biopsies from African American Multiple Myeloma Patients Using Imaging Mass Cytometry

Feasibility and Implementation of the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Initial Results from the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network

Evaluating Diagnostic Performance of Light Chain Dimerization By Mass Spectrometry to Distinguish between AL Amyloidosis and Monoclonal Gammopathy of Undetermined Significance

Impact of Absolute Lymphocyte Counts (ALC) on Outcomes Following Bispecific Antibody Therapy in Patients with Relapsed/Refractory Multiple Myeloma Patients: A Single Center Real-World Experience

Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Clinical Outcomes in Black Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 Monumental-1 Study

Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Convenience Versus Continuity: A Natural History Study of a Newly Opened Plasma Cell Disorders Clinic in an Underserved Community and Desire for Transfer of Care Among Previously Diagnosed Patients

Real-World Experience with Elotuzumab, Pomalidomide, and Dexamethasone As Second or Third-Line Therapy in Relapsed and Refractory Multiple Myeloma

Outcomes of Patients with Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from the LocoMMotion + MoMMent Studies

Novel Assay for Quantification of Free Light Chain (FLC) Dimers in Serum of Patients with Plasma Cell Dyscrasias

Treatment Patterns and Outcomes for Patients with Newly Diagnosed Multiple Myeloma Post-Stem Cell Transplantation Who Received Lenalidomide As First Line Maintenance Therapy (PREAMBLE)

Selinexor, Ixazomib, Pomalidomide and Dexamethasone in Functionally High-Risk Multiple Myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) Sub-Protocol Y3

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma

Use of Combination Premedication Prior to Motixafortide Administration Reduced Severity and Frequency of AEs in the Phase 3 Genesis Trial - a Single Center Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only